These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 23404426)
1. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors. Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426 [TBL] [Abstract][Full Text] [Related]
2. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172 [TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
4. cFos is critical for MCF-7 breast cancer cell growth. Lu C; Shen Q; DuPré E; Kim H; Hilsenbeck S; Brown PH Oncogene; 2005 Sep; 24(43):6516-24. PubMed ID: 16027729 [TBL] [Abstract][Full Text] [Related]
5. Activation and inhibition of the AP-1 complex in human breast cancer cells. Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534 [TBL] [Abstract][Full Text] [Related]
6. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression. Zhang B; Zhang X; Tang B; Zheng P; Zhang Y Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650 [TBL] [Abstract][Full Text] [Related]
7. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Smith LM; Wise SC; Hendricks DT; Sabichi AL; Bos T; Reddy P; Brown PH; Birrer MJ Oncogene; 1999 Oct; 18(44):6063-70. PubMed ID: 10557095 [TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells. Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392 [TBL] [Abstract][Full Text] [Related]
9. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells. Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898 [TBL] [Abstract][Full Text] [Related]
10. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Zhao B; Yu W; Qian M; Simmons-Menchaca M; Brown P; Birrer MJ; Sanders BG; Kline K Mol Carcinog; 1997 Jul; 19(3):180-90. PubMed ID: 9254885 [TBL] [Abstract][Full Text] [Related]
11. Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Yang L; Kim HT; Munoz-Medellin D; Reddy P; Brown PH Cancer Res; 1997 Oct; 57(20):4652-61. PubMed ID: 9377582 [TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Zhang X; Wang ZY Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601 [TBL] [Abstract][Full Text] [Related]
13. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Osipo C; Gajdos C; Cheng D; Jordan VC J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267 [TBL] [Abstract][Full Text] [Related]
14. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041 [TBL] [Abstract][Full Text] [Related]
15. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054 [TBL] [Abstract][Full Text] [Related]
16. The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study. Namazi S; Rostami-Yalmeh J; Sahebi E; Jaberipour M; Razmkhah M; Hosseini A Biomed Pharmacother; 2014 Jun; 68(5):565-71. PubMed ID: 24975086 [TBL] [Abstract][Full Text] [Related]
17. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells. Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818 [TBL] [Abstract][Full Text] [Related]
18. AP-1 blockade inhibits the growth of normal and malignant breast cells. Ludes-Meyers JH; Liu Y; Muñoz-Medellin D; Hilsenbeck SG; Brown PH Oncogene; 2001 May; 20(22):2771-80. PubMed ID: 11420689 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Kim CG; Choi BH; Son SW; Yi SJ; Shin SY; Lee YH Cell Signal; 2007 Jun; 19(6):1290-300. PubMed ID: 17307334 [TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]